Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer

Although the use of stereotactic ablative radiotherapy (SABR) for stage I small cell lung cancer is in its infancy, there are many reasons to believe that with more time and experience, it could emerge as the standard of care in inoperable patients, and perhaps even have equipoise with surgery for o...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Vivek, Simone, Charles B., Zhen, Weining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746093/
https://www.ncbi.nlm.nih.gov/pubmed/26764248
http://dx.doi.org/10.1634/theoncologist.2015-0348
_version_ 1782414761355378688
author Verma, Vivek
Simone, Charles B.
Zhen, Weining
author_facet Verma, Vivek
Simone, Charles B.
Zhen, Weining
author_sort Verma, Vivek
collection PubMed
description Although the use of stereotactic ablative radiotherapy (SABR) for stage I small cell lung cancer is in its infancy, there are many reasons to believe that with more time and experience, it could emerge as the standard of care in inoperable patients, and perhaps even have equipoise with surgery for operable patients. Reporting of modeling studies and as much clinical data as possible are very much needed.
format Online
Article
Text
id pubmed-4746093
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-47460932016-02-17 Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer Verma, Vivek Simone, Charles B. Zhen, Weining Oncologist Editorial Although the use of stereotactic ablative radiotherapy (SABR) for stage I small cell lung cancer is in its infancy, there are many reasons to believe that with more time and experience, it could emerge as the standard of care in inoperable patients, and perhaps even have equipoise with surgery for operable patients. Reporting of modeling studies and as much clinical data as possible are very much needed. AlphaMed Press 2016-02 2016-01-13 /pmc/articles/PMC4746093/ /pubmed/26764248 http://dx.doi.org/10.1634/theoncologist.2015-0348 Text en ©AlphaMed Press
spellingShingle Editorial
Verma, Vivek
Simone, Charles B.
Zhen, Weining
Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title_full Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title_fullStr Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title_full_unstemmed Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title_short Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
title_sort stereotactic radiotherapy for stage i small cell lung cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746093/
https://www.ncbi.nlm.nih.gov/pubmed/26764248
http://dx.doi.org/10.1634/theoncologist.2015-0348
work_keys_str_mv AT vermavivek stereotacticradiotherapyforstageismallcelllungcancer
AT simonecharlesb stereotacticradiotherapyforstageismallcelllungcancer
AT zhenweining stereotacticradiotherapyforstageismallcelllungcancer

Ejemplares similares